Abstract 139P
Background
The incidence of Young Onset Colorectal Cancer (YO-CRC) has been increasing globally over the last few years.
Methods
Retrospective study based on data extraction from medical records at two Cancer centers, in Crete and Cyprus from 1999 to 2023. Patients were managed according to standard of care treatment and contemporary guidelines. Clinical and molecular data were collected and correlated with DFS, PFS and OS using SPSS software.
Results
A total of 334 patients were identified; 53% were female and the median age at diagnosis was 44 years (range 18-50); 68% colon and 32% rectal cancers. The median time between onset of symptoms and diagnosis was 3 months. Commonest presenting symptoms were bleeding per rectum (37,4%), weight loss (36,2%), change in bowel habit (27,5%) and bloating (19,5%). The median BMI of patients was 25. YO-CRC represented just under 6% of all colorectal cases. Molecular testing was done in patients with available tissue either prospectively or retrospectively. Table: 139P
| AJCC Stage | 3-year DFS | 5-year OS | |
| Stage I (8,6%) | 100% | 100% | |
| Stage II (23,9%) | 78,7% | 91,2% | |
| Stage III (38%) | 65,6% | 69% | |
| Median PFS | 5-year OS | ||
| Stage IV (29,5%) | 7 months | 20,5% | |
| Mutations and MSI status according to the site of the tumor | |||
| Right colon (26,9%) | Left colon (72,5%) | Overall | |
| MSH | 27,7% | 9% | 16% (20/125) |
| ALL RAS | 44,4% | 50% | 48,4% (59/122) |
| BRAF | 13,4% | 6,1% | 8,3 (8/96) |
Conclusions
Patients with YO-CRC present with similar pathogenic mutations as their older counterparts. More YO-CRC are diagnosed with metastatic disease at presentation than expected.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.